Haruki Uojima

Sagamihara, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 146 publications

Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.

Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens.

Journal: Journal of gastroenterology and hepatology

Published: August 13, 2026

Reply to "Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS-Guided Versus Percutaneous Liver Biopsy".

Reply to "Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS-Guided Versus Percutaneous Liver Biopsy".

Journal: Journal of gastroenterology and hepatology

Published: July 30, 2026

Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety.

Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety.

Journal: Cancers

Published: July 26, 2026

B cell receptor-associated protein 31 levels in serum-derived extracellular vesicles are associated with therapeutic response and prognosis in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a multicenter study.

B cell receptor-associated protein 31 levels in serum-derived extracellular vesicles are associated with therapeutic response and prognosis in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a multicenter study.

Journal: Journal of gastroenterology

Published: April 30, 2026

Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab.

Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 19, 2026

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 05, 2026

Utilization Trends of Colorectal Endoscopic Submucosal Dissection Following Reimbursement Revision and During the COVID-19 Pandemic: An Interrupted Time-Series Analysis Using a Large Japanese Claims Database.

Utilization Trends of Colorectal Endoscopic Submucosal Dissection Following Reimbursement Revision and During the COVID-19 Pandemic: An Interrupted Time-Series Analysis Using a Large Japanese Claims Database.

Journal: Digestive diseases and sciences

Published: March 08, 2026

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.

Journal: International journal of clinical oncology

Published: February 27, 2026

Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

Journal: Alimentary pharmacology & therapeutics

Published: January 25, 2026

A Prospective Observational Study of AUDIT-based Risk Stratification and Drinking Guidance Provided by Hepatologists in Patients with Alcoholic Liver Disease.

A Prospective Observational Study of AUDIT-based Risk Stratification and Drinking Guidance Provided by Hepatologists in Patients with Alcoholic Liver Disease.

Journal: Internal medicine (Tokyo, Japan)

Published: January 14, 2026

Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection.

Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection.

Journal: Journal of medical virology

Published: January 13, 2026

Mendelian Randomization Using a Japanese GWAS Identifies an HLA-Linked Causal Effect of Chronic Hepatitis B on Cholangiocarcinoma Risk.

Mendelian Randomization Using a Japanese GWAS Identifies an HLA-Linked Causal Effect of Chronic Hepatitis B on Cholangiocarcinoma Risk.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: December 02, 2025

Showing 1-12 of 146

Last Updated: 09/26/2026